Clinical Trials Browser

Phase 1/2 × Recruiting × Biliary Tract Neoplasms × Clear all

Biliary Tract Neoplasms, Stomach Neoplasms

NCT07038343 2026-05-13

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Biliary Tract Neoplasms, Carcinoma, Lung Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Small Cell Lung Carcinoma

NCT06239194 2026-05-06

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

285 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT06708663 2026-04-16

HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours

Phase 1/2 Recruiting

124 enrolled

DermatologicGastrointestinal

Biliary Tract Neoplasms, Melanoma

NCT06431490 2026-04-08

A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer

Phase 1/2 Recruiting

102 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT05849480 2026-03-24

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Phase 1/2 Recruiting

60 enrolled

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms

NCT06938321 2026-03-03

A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer

Phase 1/2 Recruiting

135 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT05523947 2026-02-24

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

Phase 1/2 Recruiting

147 enrolled

BreastGastrointestinal

Biliary Tract Neoplasms, Breast Neoplasms, Stomach Neoplasms

NCT05150691 2026-01-28

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

796 enrolled

BreastGastrointestinalGynecologicThoracic

Bile Duct Neoplasms, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06428409 2026-01-22

MK-9999-02A

Phase 1/2 Recruiting

220 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Colorectal Neoplasms

NCT06548412 2026-01-20

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

Phase 1/2 Recruiting

50 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT06943521 2025-12-11

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Phase 1/2 Recruiting

27 enrolled

BreastEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Endometrial Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05482893 2025-11-04

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Phase 1/2 Recruiting

258 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT04956640 2025-09-25

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Phase 1/2 Recruiting

540 enrolled

GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06975410 2025-08-01

Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

Phase 1/2 Recruiting

80 enrolled

GastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasm Metastasis, Vulvar Neoplasms

NCT05592626 2025-07-09

START-001

Phase 1/2 Recruiting

365 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Abdominal Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Genital Neoplasms, Female, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms, Urogenital Neoplasms, Vulvar Diseases, Vulvar Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Epstein-Barr Virus Infections, Papillomavirus Infections, Microsatellite Instability, Small Cell Lung Carcinoma

NCT05784688 2025-03-30

Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

140 enrolled

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Colorectal Neoplasms

NCT06819215 2025-02-11

Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

188 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Biliary Tract Neoplasms, Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT06792435 2025-02-07

XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.

Phase 1/2 Recruiting

240 enrolled

GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

Clinical Trials

Study for AZD4360 in Participants With Advanced Solid Tumours

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours

A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

MK-9999-02A

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

START-001

Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors

XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.